Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
about
A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.Emerging drugs for endometrial cancer.Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.
P2860
Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Combinatorial therapy using do ...... y of endometrial cancer cells.
@en
Combinatorial therapy using dovitinib and ICI182.780
@nl
type
label
Combinatorial therapy using do ...... y of endometrial cancer cells.
@en
Combinatorial therapy using dovitinib and ICI182.780
@nl
prefLabel
Combinatorial therapy using do ...... y of endometrial cancer cells.
@en
Combinatorial therapy using dovitinib and ICI182.780
@nl
P2093
P1476
Combinatorial therapy using do ...... y of endometrial cancer cells.
@en
P2093
Antonio Llombart-Cussac
Cristina Mirantes
Maria Alba Dosil
Mónica Domingo
Nuria Eritja
Xavier Dolcet
Xavier Matias-Guiu
P304
P356
10.1158/1535-7163.MCT-13-0794
P577
2014-01-21T00:00:00Z